文章核心观点 - 即将发布的Royalty Pharma报告预计季度每股收益下降40%，营收下降40.6%，分析特定指标预测能提供有价值见解 [1][4] 公司业绩预测 - 预计季度每股收益0.96美元，同比下降40% [1] - 预计营收6.7145亿美元，同比下降40.6% [1] 预测指标变化 - 过去30天该季度每股收益共识预测无修订 [2] 预测重要性 - 盈利预测修订是预测投资者对股票潜在行为的关键指标，与股票短期价格表现密切相关 [3] 特定产品营收预测 - “Revenue - Royalty Receipts - Growth Products - Cystic fibrosis franchise”预计达2.0562亿美元，同比变化-5.1% [6] - “Revenue - Royalty Receipts - Growth Products - Tysabri”预计达6915万美元，同比变化-19.5% [7] - “Revenue - Royalty Receipts - Growth Products - Imbruvica”预计达4972万美元，同比变化-28% [7] - “Revenue - Royalty Receipts - Growth Products - Xtandi”预计达3952万美元，同比变化-9.7% [8] - “Revenue - Royalty Receipts - Growth Products - Promacta”预计达4138万美元，同比变化-16.5% [8] - “Revenue - Royalty Receipts - Growth Products - Trelegy”预计达6773万美元，同比变化+40.3% [9] - “Revenue - Royalty Receipts - Growth Products - Nurtec ODT”预计达643万美元，同比变化+22.2% [10] - “Revenue - Royalty Receipts - Growth Products - Cabometyx/Cometriq”预计达1827万美元，同比变化+17.2% [11] - “Revenue - Royalty Receipts - Growth Products - Evrysdi”预计达3551万美元，同比变化+102.5% [12] - “Revenue - Royalty Receipts - Growth Products - Trodelvy”预计达1030万美元，同比变化+30.2% [13] - “Revenue - Royalty Receipts - Growth Products - Tremfya”预计达3847万美元，同比变化+21.8% [14] 股价表现与评级 - 过去一个月，公司股价回报率为-2.7%，而Zacks标准普尔500综合指数变化为-1.6% [15] - 目前公司Zacks评级为3（持有），近期表现可能与整体市场一致 [15]